Growth inhibition and enhanced chemosensitivity induced by down-regulation of Aurora-A in human renal cell carcinoma Caki-2 cells using short hairpin RNA

Terakawa,Tomoaki; Miyake,Hideaki; Kumano,Masafumi; Fujisawa,Masato

doi:10.3892/ol.2011.295

Growth inhibition and enhanced chemosensitivity induced by down-regulation of Aurora-A in human renal cell carcinoma Caki-2 cells using short hairpin RNA

Authors:
- Tomoaki Terakawa
- Hideaki Miyake
- Masafumi Kumano
- Masato Fujisawa
View Affiliations

Affiliations: Division of Urology, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan
Published online on: April 28, 2011 https://doi.org/10.3892/ol.2011.295
Pages: 713-717

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The objective of this study was to investigate the inhibitory effects of Aurora-A expression on the growth and chemosensitivity of Caki-2 cells in human renal cell carcinoma (RCC). Caki-2 cells were established, in which an expression vector containing short hairpin RNA (shRNA) targeting Aurora-A was introduced (Caki-2/sh-A). The growth and sensitivity of chemotherapeutic agents in Caki-2/sh-A cells were compared to those in Caki-2 cells transfected with control vector alone (Caki-2/C). The expression levels of both Aurora-A mRNA and protein in Caki-2/sh-A cells were less than 10% of those in Caki-2/C cells. The in vitro growth of Caki-2/sh-A cells was significantly inferior to that of Caki-2/C cells, and the proportion of Caki-2/sh-A cells in the G2-M phase was significantly greater compared to that of Caki-2/C cells. In addition, the expression level of Bax in Caki-2/sh-A cells was significantly higher as compared to that in Caki-2/C cells, while phosphorylated Akt in Caki-2/sh-A cells was markedly down-regulated compared to that in Caki-2/C cells. Among several chemotherapeutic agents examined, the most significant difference between Caki-2/sh-A and Caki-2/C cells was observed in the sensitivity to docetaxel. Thus, the IC50 value of docetaxel in Caki-2/sh-A cells was decreased by approximately 90% compared to that in Caki-2/C cells. Treatment of Caki-2/sh-A cells, but not Caki-2/C ones, with 5 nM docetaxel resulted in the induction of apoptotic cell death accompanying the induction of p53. The findings suggest that the suppression of Aurora-A expression using shRNA is a useful therapeutic strategy against RCC through growth inhibition as well as enhanced chemosensitivity.

View Figures

View References

1	Nigg EA: Mitotic kinases as regulators of cell division and its checkpoints. Nat Rev Mol Cell Biol. 2:21–32. 2001. View Article : Google Scholar : PubMed/NCBI
2	Carmena M and Earnshaw WC: The cellular geography of aurora kinase. Nat Rev Mol Cell Biol. 4:842–854. 2003. View Article : Google Scholar : PubMed/NCBI
3	Warner SL, Bearss DJ, Han H and von Hoff DD: Targeting aurora-2 kinase in cancer. Mol Cancer Ther. 2:589–595. 2003.PubMed/NCBI
4	Fukushige S, Waldman FM, Kimura M, Abe T, Furukawa T, Sunamura M, Kobari M and Horii A: Frequent gain of copy number on the long arm of chromosome 20 in human pancreatic adenocarcinoma. Genes Chromosomes Cancer. 19:161–169. 1997. View Article : Google Scholar : PubMed/NCBI
5	Isola JJ, Kallioniemi OP, Chu LW, Fuqua SA, Hilsenbeck SG, Osborne CK and Waldman FM: Genetic aberrations detected by comparative genomic hybridization predict outcome in node-negative breast cancer. Am J Pathol. 147:905–911. 1995.PubMed/NCBI
6	Zhou H, Kuang J, Zhong L, Kuo WL, Gray JW, Sahin A, Brinkley BR and Sen S: Tumor amplification kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. Nat Genet. 20:189–193. 1998. View Article : Google Scholar : PubMed/NCBI
7	Bischoff JR, Anderson L, Zhu Y, Mossie K, Ng L, Souza B, Schryver B, Flanagan P, Clairvoyant F, Ginther C, Chan CS, Novotny M, Slamon DJ and Plowman GD: A homologue of Drosophila aurora kinase is oncogenic and amplifies in human colorectal cancers. EMBO J. 17:3052–3065. 1998.PubMed/NCBI
8	Drucker BJ: Renal cell carcinoma: current status and future prospects. Cancer Treat Rev. 31:536–545. 2005. View Article : Google Scholar : PubMed/NCBI
9	Bodmer D, van den Hurk W, van Groningen JJ, Eleveld MJ, Martens GJ, Weterman MA and van Kessel AG: Understanding familial and non-familial renal cell cancer. Hum Mol Genet. 11:2489–2498. 2002. View Article : Google Scholar : PubMed/NCBI
10	Kurahashi T, Miyake H, Hara I and Fujisawa M: Significance of Aurora-A expression in renal cell carcinoma. Urol Oncol. 25:128–133. 2007. View Article : Google Scholar : PubMed/NCBI
11	Miyake H, Nelson C, Rennie PS and Gleave ME: Overexpression of insulin-like growth factor binding protein-5 helps accelerate progression to androgen-independence in the human prostate LNCaP tumor model through activation of phosphatidylinositol 3′-kinase pathway. Endocrinology. 141:2257–2265. 2000.PubMed/NCBI
12	Miyake H, Hara I, Kurahashi T, Inoue TA, Eto H and Fujisawa M: Quantitative detection of micrometastases in pelvic lymph nodes in patients with clinically localized prostate cancer by real-time reverse transcriptase-PCR. Clin Cancer Res. 13:1192–1197. 2007. View Article : Google Scholar
13	Miyake H, Yamanaka K, Muramaki M, Hara I and Gleave ME: Therapeutic efficacy of adenoviral-mediated p53 gene transfer is synergistically enhanced by combined use of antisense oligodeoxynucleotide targeting clusterin gene in a human bladder cancer model. Neoplasia. 7:171–179. 2005. View Article : Google Scholar
14	Tanaka E, Hashimoto Y, Ito T, Okumura T, Kan T, Watanabe G, Imamura M, Inazawa J and Shimada Y: The clinical significance of Aurora-A/STK15/BTAK expression in human esophageal squamous cell carcinoma. Clin Cancer Res. 11:1827–1834. 2005. View Article : Google Scholar : PubMed/NCBI
15	Gritsko TM, Coppola D, Paciga JE, Yang L, Sun M, Shelley SA, Fiorica JV, Nicosia SV and Cheng JQ: Activation and overexpression of centrosome kinase BTAK/Aurora-A in human ovarian cancer. Clin Cancer Res. 9:1420–1426. 2003.PubMed/NCBI
16	Guan Z, Wang XR, Zhu XF, Huang XF, Xu J, Wang LH, Wan XB, Long ZJ, Liu JN, Feng GK, Huang W, Zeng YX, Chen FJ and Liu Q: Aurora-A, a negative prognostic marker, increases migration and decreases radiosensitivity in cancer cells. Cancer Res. 67:10436–10444. 2007. View Article : Google Scholar : PubMed/NCBI
17	Liu X, Shi Y, Woods KW, Hessler P, Kroeger P, Wilsbacher J, Wang J, Wang JY, Li C, Li Q, Rosenberg SH, Giranda VL and Luo Y: Akt inhibitor a-443654 interferes with mitotic progression by regulating aurora a kinase expression. Neoplasia. 10:828–837. 2008.PubMed/NCBI
18	Cha TL, Chuang MJ, Wu ST, Sun GH, Chang SY, Yu DS, Huang SM, Huan SK, Cheng TC, Chen TT, Fan PL and Hsiao PW: Dual degradation of aurora A and B kinases by the histone deacetylase inhibitor LBH589 induces G2-M arrest and apoptosis of renal cancer cells. Clin Cancer Res. 15:840–850. 2009. View Article : Google Scholar : PubMed/NCBI
19	Zhou J and Giannakakou P: Targeting microtubules for cancer chemotherapy. Current Med Chem. 5:665–671. 2005.
20	Mazumdar A, Henderson YC, El-Naggar AK, Sen S and Clayman GL: Aurora kinase A inhibition and paclitaxel as targeted combination therapy for head and neck squamous cell carcinoma. Head Neck. 31:625–634. 2009. View Article : Google Scholar : PubMed/NCBI
21	Tanaka E, Hashimoto Y, Ito T, Kondo K, Higashiyama M, Tsunoda S, Ortiz C, Sakai Y, Inazawa J and Shimada Y: The suppression of aurora-A/STK15/BTAK expression enhances chemosensitivity to docetaxel in human esophageal squamous cell carcinoma. Clin Cancer Res. 13:1331–1340. 2007. View Article : Google Scholar : PubMed/NCBI
22	Lee HH, Zhu Y, Govindasamy KM and Gopalan G: Downregulation of Aurora-A overrides estrogen-mediated growth and chemoresistance in breast cancer cells. Endocr Relat Cancer. 15:765–775. 2008. View Article : Google Scholar : PubMed/NCBI